Mark Cziraky, PharmD, CLS: Biosimilars and Real-World Data

Mark Cziraky, PharmD, CLS, explains why real-world data are key in the biosimilars marketplace.
June 11, 2018


Transcript:

How important are real-world data about the safety and efficacy of biosimilars?

Yeah, I think they’re extremely important; real-world evidence and using real-world data to generate real-world evidence is extremely important in this area. Just by the nature of these therapies there is potential for some concern around their effectiveness compared to the comparative agent that they’re built from. So therefore, the fact [is] that we want to get more evidence of their use in the marketplace to show that they are reaching their intended outcomes and not showing the adverse effects that we hopefully won’t see with the products in the market.
 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.